Clinical trial · Supplements / medicine · 15 Nov 2026
In 160 adolescents with obesity, weekly tirzepatide for 72 weeks lowered BMI more than placebo
Source: JAMA
What the research found
A phase 3 randomized double-blind trial was published online on 15 November 2026. It ran at 31 centers in Canada, the Czech Republic, Israel, Italy, Poland, and the United States. Adolescents aged 12 to younger than 18, with obesity or with overweight plus a related complication, were assigned 2 to 1 to weekly tirzepatide (raised to 5, 10, or 15 mg as tolerated) or placebo for 72 weeks, plus a lifestyle program. Of 160 participants, 109 received tirzepatide and 51 received placebo. Mean age was 14.6 (standard deviation 1.6). 99 participants (61.9 percent) were female. Mean body weight was 109.7 kg and mean BMI was 38.6. At week 72, BMI fell 18.5 percent with tirzepatide and rose 0.5 percent with placebo (difference -19.0 percentage points, 95 percent CI -23.9 to -14.1, p<0.001). A BMI drop of at least 5 percent occurred in 79.6 percent versus 28.5 percent (risk difference 51.2 percentage points, 95 percent CI 36.3 to 66.1, p<0.001). All 10 key secondary outcomes favored tirzepatide. The most common adverse events were gastrointestinal and mostly mild or moderate. The abstract does not give discontinuation counts. Registry NCT06075667. This trial tested tirzepatide in adolescents. It is not a dosing guide. DOI 10.1001/jama.2026.23420. Not medical advice.
Evidence level: Clinical trial. This is among the stronger kinds of evidence, but one study rarely settles a question.
Not medical advice. Not a substitute for a prescribed medicine. Off-label prescription use is clinician-only. VitaLonga does not diagnose, treat, or cure disease. Never start, stop, or replace a prescription with a supplement on the basis of a headline.
More supplements / medicine news
- In 130 women after menopause, date palm pollen lined up with higher sexual-function scores over two months
- In 914 Mexican adolescents, about half had vitamin D deficiency, and girls had lower levels than boys
- In 38 healthy adults, a vitamin D3 bolus lined up with uneven next-day chromatin shifts
- In normal-aging mice, acarbose lined up with better spatial memory, and the same pattern did not hold in an Alzheimer model
- In 23 adults with overweight or obesity, plant sterol supplementation raised a blood sterol and did not change LDL cholesterol